Mereo Faces Lawsuit Alleging False Setrusumab Data

Edgen Stock·Mar 17 2026, 16:21

Share to

Share to

Copy link

Key Takeaways

Mereo BioPharma Group is the target of a class-action lawsuit alleging the company misled investors about the clinical trial data for its drug, setrusumab. Announced on March 17, 2026, the legal action covers a 30-month period and introduces significant legal and financial risk for the NASDAQ-listed company.

Lawsuit Filed: Bronstein, Gewirtz & Grossman, LLC filed a class-action suit against Mereo BioPharma (MREO) for alleged violations of federal securities laws.
Misleading Statements Alleged: The lawsuit claims the company made false statements regarding the ability of its drug, setrusumab, to achieve statistical significance in clinical trials.
30-Month Class Period: The legal action covers investors who purchased MREO securities between June 5, 2023, and December 26, 2025, with an April 6, 2026 deadline for lead plaintiff applications.

Lawsuit Alleges Misleading Statements on Setrusumab Trials

Mereo BioPharma Group faces a class-action lawsuit filed by the law firm Bronstein, Gewirtz & Grossman, LLC, which alleges the company and certain officers violated federal securities laws. The legal action, announced March 17, 2026, seeks to recover damages for investors who acquired Mereo securities during the specified class period.

The core of the complaint centers on claims that the clinical-stage biopharmaceutical company issued materially false and misleading statements about its drug candidate, setrusumab. Specifically, the lawsuit alleges Mereo misrepresented setrusumab's ability to achieve statistical significance in clinical studies, directly challenging the integrity of the company's reported research and development progress.

Investors Face April 6 Deadline for Lead Plaintiff Status

The lawsuit covers a 30-month class period for all individuals and entities that purchased Mereo BioPharma securities from June 5, 2023, through December 26, 2025. This extended timeframe suggests the allegations pertain to a sustained pattern of communication from the company regarding its clinical pipeline.

Multiple law firms, including Holzer & Holzer, LLC, are now publicizing an April 6, 2026, deadline for affected shareholders to petition the court for appointment as lead plaintiff. This procedural milestone escalates the legal pressure on Mereo, signaling that the litigation is advancing and potentially increasing near-term volatility for MREO stock as the market digests the financial and reputational risks.